

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Benzylpenicillin Sodium 600mg Intravenous/Intramuscular

By registered health care professionals for

Suspected Meningococcal disease

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 128

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

2. Medicines practice guideline 2: Patient group directions

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care <u>PGD</u> website FAQs

3. PGD development

Refer to the <u>NICE PGD competency framework for people developing PGDs</u>

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the NICE PGD competency framework for people authorising PGDs

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

5. PGD adoption by the provider

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the <u>NICE PGD competency framework for health professionals using PGDs</u>

	Requirements of registered Healthcare professionals working under the PGD	
Qualifications and	Registered healthcare professionals, working within or	
professional registration	contracted by the Manx Care, GP practice or Hospice who are	
	permitted staff groups outlined within the current PGD policy	
	Pharmacists must be practising in Manx Care authorised	
	premises i.e. contracted pharmacy premises	
Initial training	Knowledge of current guidelines and the administration of	
	the drug specified in this PGD/BNF and of the inclusion and	
	exclusion criteria	
	Training which enables the practitioner to make a clinical	
	assessment to establish the need for the medication covered	
	by this PGD	
	Local training in the use of PGDs	
Competency	Staff will be assessed on their knowledge of drugs and clinical	
assessment	assessment as part the competency framework for registered	
	health professionals using PGDs	
Ongoing training and	The registered health care professionals should make sure they	
competency	are aware of any changes to the recommendations for this	
	medication; it is the responsibility of the registered health care	
	professionals to keep up to date with continuing professional	
	development. PGD updates will be held every two years	

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

7. Clinical Conditions

Clinical condition or	Suspected meningococcal disease		
situation to which this			
PGD applies			
Inclusion criteria	Suspected meningococcal disease		
Exclusion criteria	Penicillin hypersensitivity (second choice Ceftriaxone)		
	Cross allergy to other beta-lactams such as Cephalosporins should		
	be taken into account		
Cautions (including any	Hypersensitivity and anaphylaxis		
relevant action to be	Serum sickness like reactions		
taken)	Reduce dose in severe renal impairment (consult product		
	literature)		
	It should be recognised that any patient with a history of		
	allergy, especially to drugs, is more likely to develop a		
	hypersensitivity after administration and if an allergic reaction		
	occurs the drug should be withdrawn and appropriate		
	treatment given		
	Delayed absorption from the intramuscular depot may occur		
	in diabetics		
Arrangements for referral	Patient should be referred to a more experienced clinical		
for medical advice	practitioner for further assessment		
Action to be taken if	Patient should be referred to a more experienced clinical		
patient excluded	practitioner for further assessment		
Action to be taken if	A verbal explanation should be given to the patient on: the		
patient declines	need for the medication and any possible effects or potential		
treatment	risks which may occur as a result of refusing treatment		
	This information must be documented in the patients' health		
	records		
	Any patient who declines care must have demonstrated		
	capacity to do so		
	Where appropriate care should be escalated		

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

8. Details of the medicine

Name form and strongth	Donay de anicilia Inication COOma
Name, form and strength	Benzylpenicillin Injection 600mg
of medicine	Prosprintian Only Madising (POM)
Legal category	Prescription Only Medicine (POM)
Indicate any <u>off-label use</u>	None
(if relevant)	
Route/method of	Slow Intravenous injection or Intramuscular injection
administration	
Dose and frequency	 Children 1-11 months old: 300mg (One half of a 600mg vial): Intravenous: Reconstitute each 600mg vial with 3.6ml of water for injections. Once completely dissolved, inject 2ml (300mg) of the resulting solution intravenously over at least one minute Intramuscular: Reconstitute each 600mg vial with 1.6ml water for injections. Once completely dissolved inject 1ml (300mg) intramuscularly
	 Children 1-9 years old: 600mg (One 600mg vial): Intravenous: Reconstitute each 600mg vial with 5ml water for injection. Once completely dissolved inject the resulting solution intravenously over at least 2 minutes Intramuscular: Reconstitute each 600mg vial with 1.6ml water for injection and inject the resulting solution intramuscularly Adults and children 10 and over: 1.2g (Two 600mg vials): Intravenous: Reconstitute each 600mg vial with 5ml of water for injection. Once completely dissolved inject the resulting solution from both vials intravenously over at least 4 minutes Intramuscular: Reconstitute each 600mg vial with 1.6ml water for injection and inject the resulting solution from each vial intramuscularly at separate sites Longer administration time is particularly important when using doses of 50mg/kg or greater to avoid CNS toxicity.
Overstitute he	doses of 50mg/kg or greater to avoid CNS toxicity One dose as described above
Quantity to be administered and/or supplied	
Maximum or minimum treatment period	One dose only
Storage	Room Temperature (store below 25°C)
Adverse effects	 Hypersensitivity reactions include urticarial, fever, joint pains, rashes, angioedema and anaphylaxis Serum sickness like reactions, haemolytic anaemia and interstitial nephritis, neutropenia, thrombocytopenia, coagulation disorders and central nervous toxicity including convulsions reported. (Especially in high doses or in severe renal impairment) Diarrhoea and antibiotic associated colitis

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

Records to be kept The administration of any medication given under a PGD	
	recorded within the patient's medical records

9. Patient information

Verbal/Written	Verbal information must be given to patients and or carers for	
information to be given	all medication being administered under a PGD	
to patient or carer	Where medication is being supplied under a PGD, written	
	patient information leaflet must also be supplied	
	A patient information leaflet is available on request	
Follow-up advice to be		
given to patient or carer	seek medical advice immediately	

10. Appendix A

References

- 1. British national formulary (BNF) available online: https://bnf.nice.org.uk
- 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
- 3. Current Health Care Professions Council standards of practice
- 4. General Pharmaceutical Council standards
- 5. The General Optical Council
- 6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves

Reference number: 128 Valid from: 03/2020 Review date: 03/2023

Version: 1 Page 6 of 6